Abrocitinib: Synthesis, Patents, and Pharmaceutical Formulations
How is Abrocitinib Made on a Large Scale?
The large-scale synthesis of abrocitinib involves a complex, multi-step chemical process. While specific proprietary details of the industrial-scale synthesis are not publicly disclosed, the general pathway involves the careful assembly of key chemical building blocks. This process requires precise control over reaction conditions, purification techniques, and quality assurance to ensure the final active pharmaceutical ingredient (API) meets stringent pharmaceutical standards. The synthesis route aims for efficiency and scalability, crucial for meeting market demand.
What Patents Protect Abrocitinib?
Abrocitinib is protected by numerous patents covering various aspects of the drug. These include patents on the chemical compound itself, its crystalline forms, pharmaceutical compositions containing abrocitinib, and methods of synthesis and use. Patent protection is a critical component of pharmaceutical research and development, allowing companies to recoup their investment in bringing new medicines to market. For detailed information on specific patents, including their status and expiry dates, resources such as DrugPatentWatch.com can be consulted [1].
What Pharmaceutical Compositions Contain Abrocitinib?
Abrocitinib is formulated into oral solid dosage forms, typically tablets, for patient administration. These pharmaceutical compositions are designed to ensure the stability, bioavailability, and consistent delivery of the active ingredient. The formulation process involves combining abrocitinib with various excipients, such as binders, fillers, disintegrants, and lubricants, which facilitate tablet manufacturing and affect how the drug is absorbed in the body. These compositions are the final product dispensed to patients.
When Do Abrocitinib Patents Expire?
The patent landscape for abrocitinib is dynamic, with multiple patents covering different aspects of the drug, each having its own expiration date. These expiration dates determine when generic versions of abrocitinib may become available. Analyzing the patent portfolio, including any granted patents and pending applications, is essential for understanding the timeline of market exclusivity. Resources like DrugPatentWatch.com offer a comprehensive overview of patent expiry timelines for pharmaceuticals [1].
Who Developed and Manufactures Abrocitinib?
Abrocitinib was developed by Pfizer Inc. Pfizer is also responsible for its commercialization and manufacturing. The company oversees the entire process from clinical development through to large-scale production and distribution of the drug.
What is Abrocitinib Used For?
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor approved for the treatment of moderate to severe atopic dermatitis in adults and adolescents who are candidates for systemic therapy. It works by selectively inhibiting JAK1, a key enzyme involved in the signaling pathways that contribute to inflammation and immune responses in conditions like atopic dermatitis.
How Does Abrocitinib Work?
Abrocitinib functions by inhibiting Janus kinase 1 (JAK1). JAK1 is an intracellular enzyme that plays a crucial role in the signaling cascades of various cytokines and growth factors. By blocking JAK1, abrocitinib disrupts the signaling pathways that lead to inflammation and immune system overactivity associated with conditions such as atopic dermatitis. This inhibition helps to reduce the itching and skin lesions characteristic of the disease.
What Are the Risks and Side Effects of Abrocitinib?
Like all medications, abrocitinib carries potential risks and side effects. Common side effects reported include acne, elevated levels of liver enzymes, upper respiratory tract infections, and nausea. More serious potential risks, which are highlighted in prescribing information, may include serious infections, major adverse cardiovascular events, thrombosis, malignancy, and decreases in hemoglobin and absolute lymphocyte count. Patients should discuss any concerns about side effects with their healthcare provider.
Are There Alternative Treatments for Atopic Dermatitis?
Yes, several alternative treatments are available for atopic dermatitis, depending on its severity and the individual patient's response to therapy. These include topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 inhibitors, and other systemic immunosuppressants. Biologic therapies, such as monoclonal antibodies targeting different inflammatory pathways (e.g., IL-4, IL-13, IL-31), are also significant alternatives for moderate to severe disease. The choice of treatment is individualized and guided by a healthcare professional.
---
Sources:
[1] DrugPatentWatch.com